Background and Objectives: Preemptive placement of permanent dialysis access is recommended in order to reduce the morbidity associated with central venous catheters. We assessed the effect of a dialysis access coordinator on preemptive access placement in veterans who are at high risk for end-stage renal disease (ESRD). Design, Setting, Participants, and Measurements: Pre-post evaluation of a dialysis access coordinator in the nephrology clinics of the Veterans Affairs Palo Alto. The access coordinator streamlined access referrals, prioritized surgical waiting lists and addressed patient barriers. We compared the frequency of preemptive access referral, surgery, and use for dialysis during the intervention period, July 1, 2013 to May 31, 2016, to a pre-intervention period, January 1, 2011 to December 31, 2013, among all patients with a predicted 1-year risk for ESRD ≥20%. Results: There were 156 patients in the historical cohort and 131 in the intervention cohort. The mean age was 69.9 ± 11.6 years and the mean estimated glomerular filtration rate was 14.5 ± 5.7 ml/min/1.73 m2. The intervention was associated with an 11.8% increase in access referral (p value = 0.03), and a 9.4% increase in completed access surgery (p value = 0.05). Increases in permanent access at the start of dialysis (15.2%), and functional permanent access at the start of dialysis (12.4%) did not reach statistical significance. Among patients who received access surgery, there was no significant difference in the prevalence of unused access. Conclusions: Implementation of an access coordinator was associated with a modest increase in preemptive access placement among patients who are at high risk for ESRD without increasing the prevalence of unused access.

Keywords:
End-stage renal disease, Vascular access, Quality improvement
1.
Lok CE, Foley R: Vascular access morbidity and mortality: trends of the last decade. Clin J Am Soc Nephrol 2013;8:1213-1219.
2.
Ishani A, Collins AJ, Herzog CA, Foley RN: Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005;68:311-318.
3.
Kosa SD, Lok CE: The economics of hemodialysis catheter-related infection prophylaxis. Semin Dial 2013;26:482-493.
4.
Lee H, Manns B, Taub K, et al: Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002;40:611-622.
5.
Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO: Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. Nephrol Dial Transplant 2006;21:1024-1031.
6.
Ramanathan V, Chiu EJ, Thomas JT, Khan A, Dolson GM, Darouiche RO: Healthcare costs associated with hemodialysis catheter-related infections: a single-center experience. Infect Control Hosp Epidemiol 2007;28:606-609.
7.
Saggi SJ, Allon M, Bernardini J, et al: Considerations in the optimal preparation of patients for dialysis. Nat Rev Nephrol 2012;8:381-389.
8.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
9.
Owen JE, Walker RJ, Edgell L, et al: Implementation of a pre-dialysis clinical pathway for patients with chronic kidney disease. Int J Qual Health Care 2006;18:145-151.
10.
Polkinghorne KR, Seneviratne M, Kerr PG: Effect of a vascular access nurse coordinator to reduce central venous catheter use in incident hemodialysis patients: a quality improvement report. Am J Kidney Dis 2009;53:99-106.
11.
Glazer S, Diesto J, Crooks P, et al: Going beyond the kidney disease outcomes quality initiative: hemodialysis access experience at Kaiser Permanente Southern California. Ann Vasc Surg 2006;20:75-82.
12.
Ackad A, Simonian GT, Steel K, et al: A journey in reversing practice patterns: a multidisciplinary experience in implementing DOQI guidelines for vascular access. Nephrol Dial Transplant 2005;20:1450-1455.
13.
O'Hare AM, Bertenthal D, Walter LC, et al: When to refer patients with chronic kidney disease for vascular access surgery: should age be a consideration? Kidney Int 2007;71:555-561.
14.
O'Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM: Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 2005;16:514-519.
15.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
16.
Drawz PE, Goswami P, Azem R, Babineau DC, Rahman M: A simple tool to predict end-stage renal disease within 1 year in elderly adults with advanced chronic kidney disease. J Am Geriatr Soc 2013;61:762-768.
17.
Lee T, Thamer M, Zhang Y, Zhang Q, Allon M: Outcomes of elderly patients after predialysis vascular access creation. J Am Soc Nephrol 2015;26:3133-3140.
18.
Tamura MK, Tan JC, O'Hare AM: Optimizing renal replacement therapy in older adults: a framework for making individualized decisions. Kidney Int 2012;82:261-269.
19.
Tangri N, Grams ME, Levey AS, et al: Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA 2016;315:164-174.
20.
Saran R, Li Y, Robinson B, et al: US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2016;67(3 suppl 1):Svii, S1-S305.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.